🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: FF MDI (PT005)

Found 8 matching trials

Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-05-31

Trial ID

NCT02766608

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg FF MDI 9.6 μg BD MDI 320 μg Symbicort® TBH 400/12 μg BID

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

PHASE3

This is a multi-center, randomized, double-blind, parallel group, chronic d...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-11

Trial ID

NCT01970878

Treatments Being Tested

GFF MDI (PT 003)GP MDI (PT001)FF MDI (PT005)Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

PHASE3

To assess the effect of treatment with Glycopyronnium (GP) MDI administered...

Status

Completed

Location

Research Site

Start Date

2016-12-29

Trial ID

NCT02937584

Treatments Being Tested

GP MDI (PT001) 14.4 μg FF MDI (PT005) 9.6 μg

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

PHASE3

This is a Phase III randomized, double-blind, parallel group, multi-center,...

Status

Completed

Location

Research Site

Start Date

2016-04-29

Trial ID

NCT02727660

Treatments Being Tested

BFF MDI (PT009) 320/9.6 μg BFF MDI (PT009) 160/9.6 μg FF MDI (PT005) 9.6 μg

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

PHASE3

This is a multicenter, randomized, double-blind, parallel group, chronic-do...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-07

Trial ID

NCT01854658

Treatments Being Tested

GFF MDI (PT003)GP MDI (PT001)FF MDI (PT005)Placebo

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

This is a Phase IIb, randomized, double blind, chronic dosing (28 days), fo...

Status

Completed

Location

Pearl Investigative Site

Start Date

2014-08-01

Trial ID

NCT02196077

Treatments Being Tested

BFF MDI 320/9.6 μg BFF MDI 160/9.6 μg BFF MDI 80/9.6 μg BD MDI 320 μg FF MDI 9.6 μg

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

PHASE3

A chronic dosing (24 weeks) study to assess the efficacy and safety GFF MDI...

Status

Completed

Location

Research Site

Start Date

2015-03-30

Trial ID

NCT02343458

Treatments Being Tested

GFF MDI (PT003)FF MDI (PT005)GP MDI (PT001)Placebo MDI

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

PHASE3

The overall objective of this study is to assess the efficacy and safety of...

Status

Completed

Location

Pearl Investigative Site

Start Date

2013-05

Trial ID

NCT01854645

Treatments Being Tested

GFF MDI GP MDI FF MDI Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)Placebo MDI

Previous Next